Fig. 1From: Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumorsStudy design for ascending (BID) and continuous schedulesBack to article page